Mizuho Securities USA LLC Has $25.16 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Mizuho Securities USA LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 88.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,092 shares of the medical research company’s stock after buying an additional 36,733 shares during the quarter. Mizuho Securities USA LLC’s holdings in Amgen were worth $25,162,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in Amgen during the 3rd quarter worth approximately $25,000. Strategic Financial Concepts LLC bought a new stake in Amgen during the second quarter worth $26,000. Hershey Financial Advisers LLC purchased a new stake in Amgen in the 2nd quarter valued at $30,000. nVerses Capital LLC bought a new position in Amgen during the 2nd quarter valued at $31,000. Finally, Bbjs Financial Advisors LLC purchased a new position in Amgen during the 2nd quarter worth $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 4.2 %

Shares of AMGN stock opened at $283.61 on Friday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The stock has a market cap of $152.45 billion, a P/E ratio of 36.31, a P/E/G ratio of 2.69 and a beta of 0.60. The company has a 50 day simple moving average of $320.85 and a two-hundred day simple moving average of $318.05.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.96 EPS. On average, research analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.17%. Amgen’s dividend payout ratio is currently 115.24%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AMGN. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday. Wolfe Research initiated coverage on Amgen in a research note on Friday. They issued a “peer perform” rating on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Finally, TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.